Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3194306 | Clinics in Dermatology | 2012 | 5 Pages |
Abstract
After a long period of relative inactivity in the introduction of new antifungals, more recently a few new drugs of already existing classes have been introduced. These represent small or large advantages and differences compared with existing available alternative therapy for deep and systemic mycoses. The 3 newest drugs include posaconazole, micafungin, and anidulafungin, whose pharmacology, toxicology, and indications are presented.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
David A. Stevens,